ALT Altimmune, Inc.
$2.09▲ +1.95%
Healthcare
Other
Volume 491.1K
Avg Volume (10D) 3.55M
Key Metrics & Fundamentals
Market Cap
$406.54M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.02 - 6.44
% vs 50 MA
-29.33%
% vs 200 MA
-38.29%
RSI-14
21.5
MACD Histogram
-0.0300
Beta (1Y vs SPY)
1.58
Free Cash Flow
-$24.25M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$21.71M
COGS
–
Operating Exp
$26.23M
Operating Income
-$26.23M
EBIT
-$26.23M
Pretax Income
-$22.83M
Net Income
-$22.83M
EPS (Diluted)
-0.12
Price & Volume History
Loading chart…
Recent News
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
GlobeNewswire · Oct 27, 2026 8:00 AM ET
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
GlobeNewswire · Oct 19, 2026 8:00 AM ET
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Zacks · Oct 7, 2026 9:02 AM ET
Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise
MarketBeat · Oct 1, 2026 7:02 AM ET
Altimmune to Participate in Stifel Cardiometabolic Forum
GlobeNewswire · Sep 23, 2026 8:00 AM ET
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Stocktwits · Sep 22, 2026 1:29 AM ET
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Zacks · Sep 11, 2026 11:30 AM ET
Altimmune’s (ALT) Three Liver Trials Move Forward At Once
Insider Monkey · Sep 7, 2026 10:27 PM ET
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
GlobeNewswire · Sep 3, 2026 8:00 AM ET
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
Zacks · Aug 19, 2026 10:55 AM ET
Financial Overview - Income Statement
Quarterly
Dec 2025
See ALT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.